Choline Bitartrate
Phase 2Small molecule
Choline Bitartrate is one of 14 small molecule programs targeting Fetal Alcohol Spectrum Disorders. It is currently in Phase 2.
3
Indications
7
Total Trials
2
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Pregnant Women
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Tirosint
IInstitut Jerome Lejeune
Approved
Tdap Vaccine
SanofiPhase 3
GBS-NN/NN2
MMinervax ApS
Phase 3
Choline Bitartrate
UUniversity of Minnesota
Phase 2
Hecolin ).
IInternational Vaccine Institute
Phase 2
Nicotinamide
MMetro International Biotech, LLC
Preclinical
IV Acetaminophen
AAFT Pharmaceuticals, Ltd.
Preclinical
Antiemetic Drug
UUniversity of West Attica
Preclinical
Shanchol
EEuBiologics Co.,Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Fetal Alcohol Spectrum Disorders2 trials
Pregnant Women1 trial
Adult1 trial
A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh
Completed·—·Phase 4·NCT01749982·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Choline Bitartrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Minnesota